IVI Partners with AcademyHealth to Address Economic Impacts on Patients and Caregivers
IVI, in partnership with AcademyHealth, released a joint report, “A Research Framework to Understand the Full Range of Economic Impacts on Patients and Caregivers,” for researchers, value assessors, and other decision-makers to address the full range of economic impacts on patients. This report was made possible through funding support from the Eugene Washington PCORI Engagement […]
IVI Comments on CMS’ Medicare Drug Price Negotiation Program
IVI submitted comments on the Centers for Medicare and Medicaid Services’ (CMS) initial guidance for the implementation of the Medicare Drug Price Negotiation Program (Medicare DPNP). We appreciate the opportunity to provide comment on this important issue. Read our full comments here. ### About IVI The Innovation and Value Initiative (IVI) is a 501(c)(3) tax-exempt, […]
IVI Co-Authors Manuscript with the RAND Corporation
IVI is pleased to share our recently published manuscript, co-authored with the RAND Corporation, in the Journal of Comparative Effectiveness Research. For this manuscript, IVI collaborated with a steering committee and surveyed patients with rheumatoid arthritis (RA) to discover a new method for engaging patients in healthcare valuation using patient-specific goals. The findings indicated that […]
IVI Statement in Response to ICER’s Health Equity Report
The Innovation and Value Initiative (IVI) has issued the following statement in response to the Institute for Clinical and Economic Review (ICER)’s recently published white paper, “Advancing Health Technology Assessment Methods that Support Health Equity.” IVI commends some of the practical learnings and supports ICER on the exploration of how “[health technology assessment] HTA can […]
4th Annual IVI Methods Summit
Hear from industry though leaders including CMS, PCORI, researchers, payers, employers, and patient advocates as they come together to provide meaningful dialogue, insight, solutions and continue working toward answering the question: How can we center equity in healthcare? Keynote Speakers: Dora Hughes, Nakela Cook, and Donna Cryer What: 4th Annual IVI Methods Summit: Rewriting the Playbook […]
IVI Launches Economic Impacts Project
IVI and AcademyHealth have partnered to develop a framework for healthcare researchers to ensure we address the full range of economic impacts on patients and caregivers. Additional information on the project is available here.
IVI Presents Poster at 2022 PCORI Annual Meeting
IVI Chief Science Officer, Rick Chapman, PhD, presented at the 2022 PCORI Annual Meeting. The presentation focused on incorporating patient priorities in patient-centered outcomes research/comparative effectiveness research (PCOR/CER) and value assessment. View the poster presentation here. Additional information on the project is available here.
IVI’s CEO, Jason Spangler, Sits Down with Inside Health Care to Discuss “Value”
In the health care world, we talk about “value-based care” in terms of putting patients first, listening to patients’ stories and giving thoughtful input. Sometimes we talk about “value-based payment models”—where providers and clinicians are encouraged to base their payment drivers on achieving positive patient outcomes rather than on a purely financial basis. IVI CEO, Jason […]
IVI Publishes Article in The Patient on Preferences for Treatments for MDD
IVI recently published a paper in The Patient – Patient-Centered Outcomes Research describing the formative research undertaken by the project team to elicit qualitative and quantitative patient input in the disease state of major depressive disorder (MDD). Based on the PAVE patient-informed value element set, the project team first identified six key factors that matter […]
HealthCore/IVI AMCP Nexus Poster
While several studies have examined real-world pharmacologic treatment patterns and costs among major depressive disorder (MDD) patients, few have examined the use of non-pharmacologic treatments. IVI recently conducted a study alongside HealthCore to describe the prevalence and predictors of treatment modality, healthcare resource utilization, and costs for newly diagnosed MDD patients. Commercially-insured US adult patients […]